Sujith Kalmadi, MD
Hematology & Oncology · Chandler, AZNPI 1508973447
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $949,824 of the $1,417,708 with a category attached, or 67.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 13.6%. Reporting peaked in 2023 at $295,584 and has fallen 66.0% since, to $100,541 in 2025. Among hematology & oncology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,524 payments — averaging $561.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cornerstone Specialty Network LLC$193K
- Johnson & Johnson$160K
- AstraZeneca$145K
- Daiichi Sankyo Inc.$106K
- Genentech USA, Inc.$106K
- Takeda Pharmaceuticals U.S.A., Inc.$65K
- plus $642K from 54 others
Across 345 payments — averaging $9576.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$842K
- Pfizer$737K
- Daiichi Sankyo Inc.$461K
- AstraZeneca$385K
- Genentech, Inc.$320K
- Bayer$140K
- plus $420K from 11 others
What the payments were for
- Consulting fees$322,57123%
- Speaking & faculty fees$949,82467%
- Travel & lodging$99,9147%
- Food & beverage$43,9223%
- Education$1,1570%
- Gifts$200%
- Other$2990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$105,758
- IMBRUVICA$99,739
- BRUKINSA$57,575
- ALUNBRIG$56,913
- PEMAZYRE$54,398
- TECENTRIQ$47,140
- DARZALEX$44,634
- CALQUENCE$39,952
- TAGRISSO$39,691
- OPDIVO$37,376
- TECVAYLI$35,348
- CARVYKTI$32,888
- Lunsumio$32,809
- RYBREVANT$30,994
- Nubeqa$29,449
- KRAZATI$26,596
- Erleada$25,012
- COSELA$21,852
- GAVRETO$18,552
- OPTUNE LUA (NOVOTTF-200T)$18,046
How this compares
$1,417,708 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 21 | $384,533 |
| BrukinsaZanubrutinib | 44 | $369,038 |
| IbrancePalbociclib | 22 | $368,954 |
| CalquenceAcalabrutinib Maleate | 24 | $365,854 |
| ImbruvicaIbrutinib | 21 | $322,783 |
| Abiraterone Acetate | 112 | $269,629 |
| Lenalidomide | 19 | $259,750 |
| XtandiEnzalutamide | 16 | $254,649 |
| RevlimidLenalidomide | 13 | $244,298 |
| LynparzaOlaparib | 12 | $202,287 |
| NubeqaDarolutamide | 11 | $152,576 |
| XareltoRivaroxaban | 68 | $55,863 |
| EliquisApixaban | 72 | $47,755 |
| Everolimus | 16 | $17,689 |
| Exemestane | 35 | $4,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence, Lynparza | $144,539 | $952,67357 claims |
| PfizerIbrance, Eliquis | $22,782 | $416,70994 claims |
| Beigene USA, Inc.Brukinsa | $47,669 | $369,03844 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $61,192 | $322,78321 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $4,320 | $269,629112 claims |
| Astellas Pharma US IncXtandi | $10,147 | $254,64916 claims |
| Bristol Myers SquibbRevlimid | $8,786 | $244,29813 claims |
| BayerNubeqa | $47,067 | $152,57611 claims |
| Johnson & JohnsonXarelto | $160,349 | $55,86368 claims |
| Lilly USA, LLCOlanzapine | $27,396 | $97635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Chandler
- Mikhail ShtivelbandChandler$42K
- Rohit SudChandler$34K
- Arun SingaviChandler$26K
- Karen Ortiz CruzChandler$26K
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.